Fig. 25
(Abstract P6). Rimiducid-dependent MyD88/CD40 costimulation enhances antitumor activity of a first-generation CD123-specific CAR
Fig. 25 | Journal for ImmunoTherapy of Cancer
(Abstract P6). Rimiducid-dependent MyD88/CD40 costimulation enhances antitumor activity of a first-generation CD123-specific CAR